DeepMed Research

Inspirna, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2010-01-01

Employees: 11

Market Cap: -

Website: http://www.rgenix.com

Clinical Trials

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Metastatic Colon Cancer

Interventions: Drug: Ompenaclid
Drug: Placebo
Drug: Bevacizumab
Drug: FOLFIRI regimen

First Posted Date: 2023-08-09

Last Posted Date: 2025-03-04

Lead Sponsor: Inspirna, Inc.

Target Recruit Count: 70

Registration Number: NCT05983367

Locations: 🇧🇪
Imelda Ziekenhuis, Bonheiden, Antwerpen, Belgium
🇧🇪
Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels Capital Region, Belgium
🇧🇪
Institut Jules Bordet, Anderlecht, Belgium

and more 24 locations

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer Metastatic
Colorectal Neoplasms
Gastric Cancer
Gastrointestinal Cancer
Gastrointestinal Neoplasms
Colorectal Cancer
KRAS Mutation-Related Tumors
Colorectal Carcinoma
Gastric Neoplasm
CRC

Interventions: Drug: ompenaclid
Drug: FOLFIRI
Drug: FOLFOX regimen
Drug: Bevacizumab

First Posted Date: 2018-07-24

Last Posted Date: 2025-04-03

Lead Sponsor: Inspirna, Inc.

Target Recruit Count: 89

Registration Number: NCT03597581

Locations: 🇺🇸
Arizona Oncology Associates, PC - HAL, Prescott Valley, Arizona, United States
🇺🇸
Arizona Oncology Associates, PC - HOP E, Tucson, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 13 locations

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Phase 1

Completed

Conditions: Endometrial Cancer
Endometrial Cancer Recurrent
Lung Cancer Recurrent
Lung Cancer
Non-small Cell Lung Cancer Metastatic
Non-small Cell Carcinoma

Interventions: Drug: RGX-104
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2016-10-04

Last Posted Date: 2025-03-26

Lead Sponsor: Inspirna, Inc.

Target Recruit Count: 146

Registration Number: NCT02922764

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States

and more 18 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy